ProPhase Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ProPhase Labs
PRPH Stock  USD 0.39  0.04  9.30%   
ProPhase Labs financial statements provide useful quarterly and yearly information to potential ProPhase Labs investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ProPhase Labs financial statements helps investors assess ProPhase Labs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ProPhase Labs' valuation are summarized below:
Gross Profit
-4.1 M
Profit Margin
(2.18)
Market Capitalization
11.9 M
Enterprise Value Revenue
3.2495
Revenue
12.8 M
We have found one hundred twenty available trending fundamental ratios for ProPhase Labs, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of ProPhase Labs recent fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 53.2 M. Enterprise Value is estimated to decrease to about 50.1 M

ProPhase Labs Total Revenue

35.48 Million

Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 1.5 M, Selling General Administrative of 29.5 M or Total Revenue of 35.5 M, as well as many indicators such as Price To Sales Ratio of 0.96, Dividend Yield of 0.13 or PTB Ratio of 0.86. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
  
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

ProPhase Labs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets111 M105.7 M42.7 M
Slightly volatile
Total Current Liabilities25.2 M24 M9.3 M
Slightly volatile
Total Stockholder Equity59.6 M56.8 M26.3 M
Slightly volatile
Property Plant And Equipment Net21.1 M20.1 M7 M
Slightly volatile
Accounts Payable11.3 M10.8 M3.5 M
Slightly volatile
Cash1.4 M1.4 M2.9 M
Pretty Stable
Non Current Assets Total53.5 M51 M16 M
Slightly volatile
Cash And Short Term Investments8 M4.3 M5 M
Slightly volatile
Net Receivables43.8 M41.8 M15.6 M
Slightly volatile
Common Stock Shares Outstanding15.2 M19.8 M15 M
Slightly volatile
Liabilities And Stockholders Equity111 M105.7 M42.7 M
Slightly volatile
Non Current Liabilities Total26.2 M24.9 M7.4 M
Slightly volatile
Inventory2.9 M3.5 M2.8 M
Slightly volatile
Other Stockholder Equity66 M62.9 M31.1 M
Slightly volatile
Total Liabilities51.4 M48.9 M16.3 M
Slightly volatile
Property Plant And Equipment Gross35 M33.4 M8.9 M
Slightly volatile
Total Current Assets27.5 M54.7 M24.8 M
Slightly volatile
Common Stock Total Equity11.9712.6469.6 K
Slightly volatile
Common Stock15.4 K16.2 K475.5 K
Slightly volatile
Property Plant Equipment12.5 M11.9 M5.6 M
Slightly volatile
Short and Long Term Debt Total25.8 M24.6 M7.4 M
Slightly volatile
Current Deferred Revenue1.8 M2.1 M2 M
Slightly volatile
Net Tangible Assets50.8 M48.4 M21.9 M
Slightly volatile
Capital Surpluse58.8 M70.9 M55.7 M
Slightly volatile
Other Liabilities1.5 M1.5 M525.5 K
Slightly volatile
Non Current Liabilities Other5.5 M5.2 M1.9 M
Slightly volatile
Long Term Debt Total6.3 M11.5 M6.7 M
Slightly volatile
Net Invested Capital43.3 M68.6 M38.7 M
Slightly volatile
Net Working Capital27.9 M30.7 M27 M
Very volatile
Capital Stock16.9 K20.7 K15.1 K
Slightly volatile
Capital Lease Obligations7 M12.8 M5.8 M
Slightly volatile

ProPhase Labs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative29.5 M31.1 M14 M
Slightly volatile
Total Revenue35.5 M51 M31.8 M
Slightly volatile
Gross Profit14 M14.6 M15.1 M
Slightly volatile
Other Operating Expenses79.7 M75.9 M37.2 M
Slightly volatile
Total Operating Expenses45.7 M43.5 M19.9 M
Slightly volatile
Depreciation And Amortization8.1 M7.7 M2.3 M
Slightly volatile
Cost Of Revenue16.8 M32.4 M17.5 M
Slightly volatile
Research Development1.4 M1.3 M903.8 K
Very volatile
Selling And Marketing Expenses1.7 M1.7 M377.6 M
Slightly volatile
Non Operating Income Net Other74.9 K71.3 K54.1 K
Slightly volatile
Non Recurring2.9 M3.2 M3.5 M
Slightly volatile
Interest Income75.4 K79.3 K106.8 K
Slightly volatile
Reconciled Depreciation7 M6.6 M2 M
Slightly volatile

ProPhase Labs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow7.3 M8.2 M4.1 M
Slightly volatile
End Period Cash Flow1.8 M1.9 M3 M
Slightly volatile
Stock Based Compensation4.3 M4.1 M1.6 M
Slightly volatile
Depreciation8.1 M7.7 M2.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.961.018.0024
Slightly volatile
Dividend Yield0.130.140.1423
Slightly volatile
PTB Ratio0.860.916.9903
Slightly volatile
Days Sales Outstanding282269158
Slightly volatile
Book Value Per Share1.93.31.5981
Slightly volatile
Average Payables517.3 K529.1 K579.4 K
Slightly volatile
Stock Based Compensation To Revenue0.07530.07170.041
Slightly volatile
Capex To Depreciation0.40.421.13
Pretty Stable
PB Ratio0.860.916.9903
Slightly volatile
EV To Sales1.441.528.039
Slightly volatile
Inventory Turnover3.486.594.9385
Slightly volatile
Days Of Inventory On Hand54.4257.2893.0464
Slightly volatile
Payables Turnover3.283.459.0034
Slightly volatile
Sales General And Administrative To Revenue0.730.70.5166
Very volatile
Average Inventory2.4 M2.5 M2.5 M
Slightly volatile
Research And Ddevelopement To Revenue0.06890.03670.0409
Slightly volatile
Capex To Revenue0.06720.0640.0368
Slightly volatile
Cash Per Share0.30.320.4395
Slightly volatile
Days Payables Outstanding11511060.4836
Slightly volatile
Intangibles To Total Assets0.180.170.1322
Very volatile
Current Ratio3.832.054.9585
Very volatile
Tangible Book Value Per Share1.732.131.2676
Slightly volatile
Receivables Turnover1.341.413.1476
Slightly volatile
Shareholders Equity Per Share1.93.31.5981
Slightly volatile
Debt To Equity0.210.390.475
Slightly volatile
Capex Per Share0.170.18340.0888
Slightly volatile
Average Receivables4.6 M5.9 M6.4 M
Pretty Stable
Revenue Per Share2.672.972.0866
Slightly volatile
Interest Debt Per Share1.241.180.6049
Slightly volatile
Debt To Assets0.220.210.1965
Slightly volatile
Graham Number9.79.237.6445
Slightly volatile
Operating Cycle245401242
Slightly volatile
Price Book Value Ratio0.860.916.9903
Slightly volatile
Days Of Payables Outstanding11511060.4836
Slightly volatile
Ebt Per Ebit1.071.210.9626
Pretty Stable
Company Equity Multiplier1.171.681.5624
Pretty Stable
Long Term Debt To Capitalization0.110.150.2266
Pretty Stable
Total Debt To Capitalization0.290.270.2517
Slightly volatile
Debt Equity Ratio0.210.390.475
Slightly volatile
Quick Ratio3.271.894.3578
Very volatile
Cash Ratio0.08430.08870.7217
Slightly volatile
Cash Conversion Cycle205261185
Very volatile
Days Of Inventory Outstanding54.4257.2893.0464
Slightly volatile
Days Of Sales Outstanding282269158
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.851.151.187
Very volatile
Price To Book Ratio0.860.916.9903
Slightly volatile
Fixed Asset Turnover2.782.927.9264
Slightly volatile
Debt Ratio0.220.210.1965
Slightly volatile
Price Sales Ratio0.961.018.0024
Slightly volatile
Asset Turnover0.530.560.92
Slightly volatile
Gross Profit Margin0.580.420.4912
Slightly volatile
Price Fair Value0.860.916.9903
Slightly volatile

ProPhase Labs Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap53.2 M56 M50.9 M
Pretty Stable
Enterprise Value50.1 M52.7 M48.1 M
Pretty Stable

ProPhase Fundamental Market Drivers

Forward Price Earnings10.0908
Cash And Short Term Investments4.7 M

ProPhase Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ProPhase Labs Financial Statements

Investors use fundamental indicators, such as ProPhase Labs' revenue or net income, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M1.8 M
Total Revenue51 M35.5 M
Cost Of Revenue32.4 M16.8 M
Stock Based Compensation To Revenue 0.07  0.08 
Sales General And Administrative To Revenue 0.70  0.73 
Research And Ddevelopement To Revenue 0.04  0.07 
Capex To Revenue 0.06  0.07 
Revenue Per Share 2.97  2.67 
Ebit Per Revenue(0.56)(0.53)

Currently Active Assets on Macroaxis

VVisa Class A
CRMSalesforce
CRMSalesforce
MSFTMicrosoft
VVisa Class A
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:
How To Invest In ProPhase
Details
Is ProPhase Stock a good investment?
Details
What is ProPhase Labs' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(1.53)
Revenue Per Share
0.689
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.24)
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY